ScholarX: Browsing ScholarWorks

Browsing by Lu, ShunAuthor

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

전체 가 나 다 라 마 바 사 아 자 차 카 타 파 하

Sort by: In order: Results/Page Authors/Record:

Showing results 1 to 16 of 16

SCIESCOPUS

Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer

Wu, Yi-Long; Dziadziuszko, Rafal; Ahn, Jin Seok; Barlesi, Fabrice; Nishio, Makoto; Lee, Dae Ho; Lee, Jong-Seok; Zhong, Wenzhao; Horinouchi, Hidehito; Mao, Weimin, et al.

ArticleIssue Date2024CitationNew England Journal of Medicine, v.390, no.14, pp 1265 - 1276PublisherMassachussetts Medical Society

SCIESCOPUS

Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC

Cho, Byoung C.; Lu, Shun; Felip, Enriqueta; Spira, Alexander I.; Girard, Nicolas; Lee, Jong-Seok; Lee, Se-Hoon; Ostapenko, Yurii; Danchaivijitr, Pongwut; Liu, Baogang, et al.

ArticleIssue Date2024CitationNEW ENGLAND JOURNAL OF MEDICINEPublisherMASSACHUSETTS MEDICAL SOC

SCIESCOPUS

Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment in Patients With EGFR-mutated, Advanced Nonsmall Cell Lung Cancer (NSCLC): Primary Results From MARIPOSA, a Phase 3, Global, Randomized, Controlled Trial (Previously presented at ESMO Congress 2023, FPN:LBA14, Byoung Chul Cho et al. - Reused with permission.)

Schuler, Martin; Cho, Byoung Chul; Felip, Enriqueta; Spira, Alexander; Girard, Niolas; Lee, Jong-Seok; Lee, Se-Hoon; Ostapenko, Yuriy; Danchaivijitr, Pongwut; Liu, Baogang, et al.

ArticleIssue Date2024CitationONCOLOGY RESEARCH AND TREATMENT, v.47, pp 260 - 261PublisherKARGER

SCIESCOPUS

Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study

Felip, Enriqueta; Cho, Byoung Chul; Gutierrez, Vanesa; Alip, Adlinda; Besse, Benjamin; Lu, Shun; Spira, Alexander I.; Girard, Nicolas; Califano, Raffaele; Gadgeel, Shirish M., et al.

ArticleIssue Date2024CitationJOURNAL OF CLINICAL ONCOLOGY, v.42, no.16PublisherLIPPINCOTT WILLIAMS & WILKINS

SCIESCOPUS

Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial open access

Yang, James Chih-Hsin; Liu, Geoffrey; Lu, Shun; He, Jianxing; Burotto, Mauricio; Ahn, Myung-Ju; Kim, Dong-Wan; Liu, XiaoQing; Zhao, Yanqiu; Vincent, Sylvie, et al.

ArticleIssue Date2023CitationJournal of Thoracic Oncology, v.18, no.12, pp 1743 - 1755PublisherElsevier Inc.

SCIESSCISCOPUS

Consensus on the lung cancer management after third-generation EGFR-TKI resistance open access

Zhou, Qing; Zhao, Hongyun; Lu, Shun; Cheng, Ying; Liu, Ying; Zhao, Mingfang; Yu, Zhuang; Hu, Chengping; Zhang, Li; Yang, Fan, et al.

ArticleIssue Date2024CitationThe Lancet Regional Health - Western Pacific, v.53PublisherElsevier Ltd

SCIESCOPUS

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Ahn, Myung-Ju; Tanaka, Kentaro; Paz-Ares, Luis; Cornelissen, Robin; Girard, Nicolas; Pons-Tostivint, Elvire; Vicente Baz, David; Sugawara, Shunichi; Cobo, Manuel; Pérol, Maurice, et al.

ArticleIssue Date2025CitationJournal of Clinical Oncology, v.43, no.3PublisherLippincott Williams and Wilkins

SCOPUSESCI

First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial

Zhou, Qing; Yu, Yan; Xing, Ligang; Cheng, Ying; Wang, Ying; Pan, Yueyin; Fan, Yun; Shi, Jianhua; Zhang, Guojun; Cui, Jiuwei, et al.

ArticleIssue Date2025CitationMed, v.6, no.1PublisherCell Press

SCIESCOPUS

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations open access

Remon, Jordi; Passiglia, Francesco; Ahn, Myung-Ju; Barlesi, Fabrice; Forde, Patrick M.; Garon, Edward B.; Gettinger, Scott; Goldberg, Sarah B.; Herbst, Roy S.; Horn, Leora, et al.

ArticleIssue Date2020CitationJOURNAL OF THORACIC ONCOLOGY, v.15, no.6, pp 914 - 947PublisherELSEVIER SCIENCE INC

SCOPUS

Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions

Wang, Yibei; Safi, Mohammed; Hirsch, Fred R.; Lu, Shun; Peters, Solange; Govindan, Ramaswamy; Rosell, Rafael; Park, Keunchil; Zhang, Jianjun J.

ArticleIssue Date2025CitationNATURE REVIEWS CLINICAL ONCOLOGYPublisherNATURE PORTFOLIO

SCIESCOPUS

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301

Cho, Byoung Chul; Ahn, Myung-Ju; Kang, Jin Hyoung; Soo, Ross A.; Reungwetwattana, Thanyanan; Yang, James Chih-Hsin; Cicin, Irfan; Kim, Dong-Wan; Wu, Yi-Long; Lu, Shun, et al.

ArticleIssue Date2023CitationJournal of clinical oncology : official journal of the American Society of Clinical Oncology, v.41, no.26, pp 4208 - 4217PublisherNLM (Medline)

SCIESCOPUS

Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study

Ramalingam, Suresh S.; Kato, Terufumi; Dong, Xiaorong; Ahn, Myung-Ju; Quang, Le-Van; Soparattanapaisarn, Nopadol; Inoue, Takako; Wang, Chih-Liang; Huang, Meijuan; Yang, James Chih-Hsin, et al.

ArticleIssue Date2024CitationJOURNAL OF CLINICAL ONCOLOGY, v.42, no.17_SUPPL, pp LBA4 - LBA4PublisherLIPPINCOTT WILLIAMS & WILKINS

SCIESCOPUS

Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC

Lu, Shun; Kato, Terufumi; Dong, Xiaorong; Ahn, Myung-Ju; Quang, Le-Van; Soparattanapaisarn, Nopadol; Inoue, Takako; Wang, Chih-Liang; Huang, Meijuan; Yang, James Chih-Hsin, et al.

ArticleIssue Date2024CitationNEW ENGLAND JOURNAL OF MEDICINE, v.391, no.7, pp 585 - 597PublisherMASSACHUSETTS MEDICAL SOC

SCIESCOPUS

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR -Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial

Camidge, D. Ross; Bar, Jair; Horinouchi, Hidehito; Goldman, Jonathan; Moiseenko, Fedor; Filippova, Elena; Cicin, Irfan; Ciuleanu, Tudor; Daaboul, Nathalie; Liu, Chunling, et al.

ArticleIssue Date2024CitationJournal of Clinical Oncology, v.42, no.25PublisherLippincott Williams and Wilkins

SCIESCOPUS

Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic open access

Dingemans, Anne-Marie C.; Soo, Ross A.; Jazieh, Abdul Rahman; Rice, Shawn J.; Kim, Young Tae; Teo, Lynette L. S.; Warren, Graham W.; Xiao, Shu-Yuan; Smit, Egbert F.; Aerts, Joachim G., et al.

ArticleIssue Date2020CitationJOURNAL OF THORACIC ONCOLOGY, v.15, no.7, pp 1119 - 1136PublisherELSEVIER SCIENCE INC

SCIESCOPUS

TROPION-Lung07: Phase III study of Dato-DXd plus pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer open access

Okamoto, Isamu; Kuyama, Shoichi; Girard, Nicolas; Lu, Shun; Franke, Fabio; Li, Ziming; Danchaivijitr, Pongwut; Han, Ji-Youn; Sun, Jong-Mu; Sugawara, Shunichi, et al.

ArticleIssue Date2024CitationFUTURE ONCOLOGY, v.20, no.37, pp 2927 - 2936PublisherTAYLOR & FRANCIS LTD

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Browsing by Lu, ShunAuthor

BROWSE